Cancer Biotherapy and Radiopharmaceuticals

Journal

Publication Venue For

  • 89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.  34:288-296. 2019
  • Imaging of HER2 with [ 89 Zr]pertuzumab in response to T-DM1 therapy.  34:209-217. 2019
  • Pazopanib combined with radiation: In vivo model of interaction.  29:247-250. 2014
  • Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.  29:12-17. 2014
  • Phase i study of a modified regimen of 90yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed cd20+ non-hodgkin lymphoma.  28:370-379. 2013
  • Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.  27:36-40. 2012
  • Progress in cancer therapy.  27:1. 2012
  • Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.  26:127-133. 2011
  • Renal dosimetry.  25:597-599. 2010
  • Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).  25:13-19. 2010
  • A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.  21:561-568. 2006
  • Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs.  21:601-606. 2006
  • Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.  21:553-560. 2006
  • Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)).  20:671. 2005
  • Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.  20:662-670. 2005
  • Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.  20:502-513. 2005
  • Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration.  20:467-478. 2005
  • Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.  20:379-390. 2005
  • Clinically useful marrow dosimetry for targeted radionuclide therapy.  20:119-122. 2005
  • Testicular uptake and radiation dose in patients receiving Zevalin™ and Pretarget™ CC49Fusion protein.  20:110-118. 2005
  • A Novel Monoclonal Antibody Design for Radioimmunotherapy.  18:751-759. 2003
  • Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: Clinical effects and hematologic toxicity.  18:317-325. 2003
  • Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.  18:393-404. 2003
  • Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.  18:209-215. 2003
  • Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.  18:231-237. 2003
  • Three-dimensional dose model for the comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 radioimmunotherapy in mice bearing intraperitoneal xenografts.  18:239-247. 2003
  • A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer.  16:125-132. 2001
  • Gene therapy for the treatment of cancer..  16:275-288. 2001
  • Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study.  16:305-315. 2001
  • Update: Gene therapy for the treatment of cancer.  16:275-288. 2001
  • Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation.  14:451-463. 1999
  • Dosimetry for radioimmunotherapy: A rapidly evolving field - Editorial.  14:67-70. 1999
  • Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.  14:167-176. 1999
  • Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.  14:363-369. 1999
  • Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody.  13:239-254. 1998
  • Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.  13:1-12. 1998
  • Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.  13:143-154. 1998
  • Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.  12:79-87. 1997
  • Synthesis and biodistribution of peptide based 99mTc/186Re- MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts.  12:55-62. 1997
  • Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin.  12:375-384. 1997
  • International Standard Serial Number (issn)

  • 1084-9785
  • Electronic International Standard Serial Number (eissn)

  • 1557-8852